

**AL-QUDS UNIVERSITY**  
**FACULTY OF GRADUATE STUDIES**



**MOLECULAR GENETICS OF COLORECTAL CANCER**  
**A COMPARATIVE STUDY BETWEEN**  
**PALESTINIAN & ISRAELI PATIENTS**

**BY**

**SAMER MOHAMMAD HAMMAD OWINEH**

**SUPERVISOR**

**PROF. HISHAM DARWISH**

Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Biochemistry and Molecular Biology. From the Faculty of Graduate Studies, at Al-Quds University, Jerusalem, Palestine

**January, 2004**

MOLECULAR GENETICS OF  
COLORECTAL CANCER


A COMPARATIVE STUDY BETWEEN  
PALESTINIAN AND ISRAELI PATIENTS

BY  
SAMER MOHAMMAD HAMMAD OWINEH

Committee Members

Signature


1. Dr. Hisham Darwish (Supervisor)

A handwritten signature in blue ink, written over a horizontal dashed line. The signature is cursive and appears to be 'Hisham Darwish'.

2. Dr. Suhail Ayesh (External Examiner)

A handwritten signature in blue ink, written over a horizontal dashed line. The signature is cursive and appears to be 'Suhail Ayesh'.

3. Dr. Rasmi Abu-Helu (Internal Examiner)

A handwritten signature in blue ink, written over a horizontal dashed line. The signature is cursive and appears to be 'Rasmi Abu-Helu'.

January, 2004

## ACKNOWLEDGMENTS:

I would like to express my sincere thanks and gratitude to my supervisors Dr Hisham Darwish for his support and assistance and to Dr Suhyel Ayesh for training and assistance in all aspects of my thesis work especially providing H19 and Heparanase probes readily synthesized for the in situ hybridization. My thanks also go to Dr Maher Zughayer for his direct supervision in samples collection from the pathology department in Almaqased hospital/ east Jerusalem, and his hard work in grading, and samples evaluations. Dr Bassam Abulebdah and his team in the Cytology Laboratory in Almaqased hospital for their assistance especially Ms Hajar and Ms Maha. Also I thank Mr Wasef Alsharif in the Molecular laboratory for his assistance in training for the in situ hybridization protocol, and Dr Sharabati for providing samples from Hebron region.

My thanks extends to Dr Nader Arber for providing samples for Israeli patients and Dr H. Hebshoosh/ Department of Pathology, Columbia University, New York, USA for the immunohistochemistry tests done for many gene products in the comparative study that included 25 patients from each ethnic group.

My thanks also go to Dr Israel Vlodaysky/ Oncology department Hadasah hospital and his team for their kindness in training for immunohistochemistry of Heparanase, and for providing Heparanase antibody for all the samples tested. Special thanks to all members of the biochemistry department at Al-Quds University and to Mr Bassam Banat for his assistance in the statistical analysis of part of this study.

## DECLARATION:

I certify that this thesis submitted for the degree of Master is the result of my own research, except where otherwise acknowledged, and that this thesis (or any part of the same) has not been submitted for a higher degree to any other university or institution.

Signature: .....

Name: Samer Mohammad Hammad Owineh

Date: January, 5, 2004

# Table of Contents

Dedication .....	III
Acknowledgments .....	IV
Abstract .....	VIII
<b>INTRODUCTION</b>	
1.1. Background of Colorectal Cancer .....	1
1.1.1. Anatomy & Histology of the colon .....	2
1.1.2. Colorectal Cancer .....	4
1.1.3. Symptoms .....	4
1.1.4. Diagnosis .....	5
1.1.5. Epidemiology .....	5
1.1.6. Colorectal Polyps .....	6
1.1.6.1. Non-neoplastic polyps .....	7
1.1.6.1. Adenomas .....	7
1.1.7. Colorectal Carcinogenesis .....	7
1.1.8. Treatment .....	8
1.1.9. Morphogenesis endoscopic & histological markers .....	8
1.1.10. Staging .....	9
1.1.10.a. Dukes Classification .....	9
1.1.10.b. Astler-Collier Modification .....	10
1.1.10.c. Tumor/ Node/ Metastasis (TNM) System .....	10
1.1.11. The Histopathologic Grade .....	11
1.1.12. Prognosis .....	11
1.1.13. Prevention .....	12

<b>1.2. Molecular Genetics of Cancer</b>	13
1.2.1. Acquired capability: self-sufficiency in growth signals	13
1.2.2. Acquired capability: insensitivity to antigrowth signals	14
1.2.3. Acquired Capability: Evading Apoptosis	15
1.2.4. Acquired Capability: Limitless Replicative Potential	17
1.2.5. Acquired Capability: Sustained Angiogenesis	18
1.2.6. Acquired Capability: Tissue Invasion and Metastasis	19
<b>1.3. Multistage Carcinogenesis</b>	21
1.3.1 Tumor suppressor genes	22
1.3.1.a. APC (Adenomatous Polyposis Coli)	22
1.3.1.b. DCC (Deleted in Colon Cancer)	23
1.3.1.c. P53	24
1.3.2. Other Genes related to DNA repair, Apoptosis & Cell cycle	25
1.3.2.a. HNPCC (Hereditary Nonpolyposis Colon Carcinoma)	25
1.3.2.b. Methylation Abnormalities	26
1.3.2.c. K-ras Gene	27
1.3.2.d. Cyclin D1 Gene	27
1.3.2.e. P27 Gene	28
1.3.2.f. Ki-67 Gene	29
1.3.2.g. HER-2/neu Gene	29
1.3.2.h. H19 Gene	30
1.3.2.i. Heparanase	32
<b>1.4. Molecular Methods for the Diagnosis of Cancer</b>	35
1.4.1. Protein based markers	35
1.4.2. RNA based markers	36
1.4.3. DNA based marker	37
 <b>Materials and Methods</b>	
<b>2.1. Samples Collection and Origin</b>	40
<b>2.2. Immunohistostaining</b>	41
2.2.1. Heparanase Enzyme Immunostaining	41
2.2.1.1 Preparation of Slides	41

2.2.1.II Deparaffinization, Rehydration and Staining	41
2.2.2. Immunostaining of Cyclin D1, B-catenin, P27, P53, Ki-67 and Her-2/neu proteins	43
2.2.3. Control Slides	44
<b>2.3 <i>In Situ</i> Hybridization</b>	<b>45</b>
2.3.1 Preparation of tissue	47
2.3.2 <i>In Situ</i> Hybridization Protocol	48
Samples Evaluation	53
<b>RESULTS</b>	<b>54</b>
<b>DISCUSSION</b>	<b>80</b>
<b>APPENDIX</b>	<b>87</b>
<b>ABBREVIATIONS</b>	<b>91</b>
<b>REFFERANCES</b>	<b>93</b>
<b>PUBLISHED ARTICLE</b>	<b>108</b>

## Abstract

### Objective:

To investigate differential expression of genes including H19, Heparanase, Ki-67, Her-2/neu, p53, p27, Cyclin D1 and B-catenin in three different populations of Colorectal Cancer patients living in the same geographical region.

### Patients and Methods:

144 colorectal cancer patients' medical files (94 Palestinians and 50 Israelis (both Ashkenazi and Sephardic)) were searched for Age, gender, Grade, Stage of the disease, smoking, and 5-year survival. Samples of paraffin embedded sections and blocks for those patients were selected from pathology departments of Palestinian and Israeli hospitals.

*In situ hybridization (ISH)* for H19 RNA, and *Immunohistochemistry (IHC)* for Heparanase, Ki-67, Her-2/neu, p53, p27, Cyclin D1 and B-catenin were performed, and the intensity of reactions were evaluated by an authorized pathologist.

### Results:

69% of Palestinian patients were between 50-72 years old. 55% were males and 45% were females. None of them was diagnosed at stage A and most of them were at B and C stages. 97% of them were at grade II. 64% of females were at B stage and 52% of males were in stage C.

60% of the Israeli patients were more than 73 years old, and were diagnosed at earlier stages and grades than Palestinian. There was no difference in H19 and Heparanase genes expression among Palestinian and Israeli patients. Heparanase expression was found 93% of all samples tested (93% for Palestinians and 96% for the Israelis).

P27 gene was expressed in 67% of the Palestinian samples compared to 33% for the Sephardic and 75% for the Ashkenazi Jews. Cyclin D1 gene was expressed in 57% of the Palestinian samples compared to 33% for the Sephardic and 25% for the Ashkenazi Jews. There were no statistical differences in the expression of p53, Her-2/neu and B-catenin among the three groups.

**Conclusion:** There were differences in gene expression in many genes tested on the three ethnic groups.

## Abstract

**الهدف:** الدراسة والتحقق من تمايز تعبير مجموعة من الجينات تشمل كل من H19, Heparanase, Ki-67, Her-2/neu, p53, p27, Cyclin D1, B-catenin في ثلاثة مجتمعات مختلفة من مرضى سرطان القولون والذين يعيشون في منطقة جغرافية واحدة.

**المرضى وطرق الفحص:** 144 ملف طبي لمرضى سرطان القولون تم اختيارها عشوائيا من أقسام التشريح المرضي في العديد من المستشفيات الإسرائيلية والفلسطينية، 94 منها لفلسطينيين و50 منها لإسرائيليين ( يهود غربيين وشرقيين أو اليهود الاشكيناز والسفرديين)، حيث تم استخراج المعلومات التالية والمتعلقة بكل مريض على حده وهي: العمر، الجنس، مرحلة المرض، تمايز الخلايا السرطانية، التدخين، النجاة لمدة خمسة سنوات بعد الإصابة، عينات من القطع السرطانية المستأصلة عبر الجراحة والمحفظة في مادة شمعية خاصة تم أخذها وتقطيعها إلى شرائح لتتم دراستها مخبريا.

تم إجراء الفحص المسمى ب (*In situ hybridization (ISH)*) لجين H19 بينما تم إجراء فحص *Immunohistochemistry (IHC)* للجينات التالية Heparanase, Ki-67, Her-2/neu, p53, p27, Cyclin D1, B-catenin حيث تم تقييم تركيز التفاعلات من قبل مشرح مرضي مختص.

**النتائج:** 69% من المرضى الفلسطينيين تقع أعمارهم بين 50-72 سنة بينما 60% من المرضى الإسرائيليين تزيد أعمارهم عن 73 سنة، 55% من المرضى الفلسطينيين كانوا ذكورا والبقية من الإناث، لم يتم تشخيص أي مريض فلسطيني في المرحلة المبكرة A حيث تم تشخيص غالبيتهم في مراحل متوسطة ومتأخرة B, C، الخلايا السرطانية كانت متوسطة التمايز عن الخلايا الطبيعية في 97% منهم، 64% من الإناث تم تشخيصهن في المرحلة B و 52% من الذكور تم تشخيصهم في المرحلة شبه المتأخرة C.

المرضى اليهود يتم تشخيصهم في مراحل مبكرة أكثر من المرضى الفلسطينيين، لم نجد أية فروقات في تعبير الجينات H19 و Heparanase بين المرضى اليهود والفلسطينيين.

لم نعد نرى الجيني Heparanase وجد في 93% من مرضى الجانبين (92% عند الفلسطينيين و 96% عند الإسرائيليين)، كما ولوحظ تعبير لجين p27 في 67% من المرضى الفلسطينيين مقارنة مع 33% من المرضى اليهود الشرقيين و 75% من المرضى اليهود الغربيين، بينما تم ذلك في جين Cyclin D1 عند 57% من المرضى الفلسطينيين مقارنة مع 33% عند اليهود الشرقيين و 25% عند اليهود الغربيين.

لم نجد أية فروقات ذات دالة إحصائية في تعبير الجينات Her-2/neu, p53, B-catenin بين الثلاثة مجتمعات المختلفة.

**الخلاصة:** يوجد العديد من الاختلافات بين مرضى سرطان القولون الفلسطينيين واليهود ومن ضمنها الاختلاف الجيني.

# INTRODUCTION

## 1.1. Background of Colorectal Cancer

The word Cancer is a popular term for a Malignant Neoplasm. Cancers arising in epithelial cells are called Carcinomas. Cancers arising in the Mesenchymal tissues are called Sarcomas. Carcinomas are further divided into Adeno-carcinomas when they have a glandular growth pattern or Squamous Cell Carcinomas when they produce recognizable squamous cells. Sometimes the cancer is composed of undifferentiated cells and designated as a poorly differentiated or undifferentiated malignant tumor or undifferentiated carcinoma or sarcoma (Cotran *et al.*, 1999).

After a quarter century of rapid advances, cancer research has generated a rich and complex body of knowledge, revealing cancer to be a disease involving dynamic changes in the genome. Where mutations produce oncogenes with dominant gain of function and tumor suppressor genes with recessive loss of function in human and animal cancer cells (Hanahan and Weinberg 2000), this makes the cell lose its normal control and start to divide in an uncontrolled manner (Coleman *et al.*, 1997). The cell will also look different in terms of shape, size and its internal components. The transformed properties are transferred upon all of the daughter cells. Cancer cells have properties of endless replication, loss of contact inhibition, invasiveness and the ability to metastasize (Morson, 1988).

Colorectal cancer is the commonest cause of death due to malignancy in nonsmokers in western countries and consumes considerable health care resources (Esteve *et al.*, 1993). There has been marginal improvement in survival from the disease in the past 50 years and there is a need to improve understanding of the fundamental mechanisms of colorectal carcinogenesis to facilitate development of

new approaches aimed at arresting and even preventing the malignant process (Coleman *et al.*, 1993; Chu *et al.*, 1994).

Clinically cancer begins with signs and symptoms of disease in the patient followed by direct visualization by imaging and biopsy, while pathologically it is the gross and microscopic morphological changes, and at the molecular level it is the presence of specific and sequential clonal genetic alterations (Cairns *et al.*, 1999). Traditionally, carcinogenesis has been thought of consisting of three major stages initiation, promotion and progression. Initiation involves the normal genome undergoing an irreversible genetic change to an altered genome; promotion is the shift from the normal process of cell differentiation to growth, and then progression to local tumor and metastases (Vogelstein *et al.*, 1988).

### **1.1.1. Anatomy and Histology of the Colon**

The Colon & Rectum or Large Bowel is a storage and absorptive organ. It starts with the Cecum where the Appendix is attached to the lower part of the Cecum. The next part is the Ascending Colon, which runs up to the Hepatic Flexure situated just under the Liver. The Transverse Colon runs transversely across the abdomen to the Splenic Flexure lying just below the Spleen. Colon then runs downwards and is called the Descending Colon down to the left lower abdominal quadrant where it makes an S-shaped loop called the Sigmoid Colon, which runs down into the Pelvis and is called the Rectum. Rectum is about 13 cm long and goes over into the Anal Canal, which ends with the Anus (Silverstein *et al.*, 1995), these features are clearly illustrated in Figure 1.1.




Figure 1.1: the human large intestine including the main parts of the colorectal canal; starting with the Appendix, Ascending Colon, Hepatic Flexure, Transverse Colon, Splenic Flexure, Descending Colon, S-shaped Sigmoid Colon, Rectum, and the Anal Canal, which ends with the Anus (Goldinger, 2000).

The colorectal wall is made up of four layers - the Mucosa, the Submucosa, the Muscularis Propria and the Serosa. The Mucosa is closest to the lumen and consists of, starting from the lumen - the Epithelium (simple columnar), Lamina Propria and Muscularis Mucosae. Followed by the Submucosa, and the Muscularis propria. The Serosa is the external coat consisting of a layer of Mesothelial cells resting on loose connective tissue outside the Muscular layer (Morson, 1988), these features are clearly illustrated in Figure 2.1




Figure 2.1: The colorectal wall including four layers - the Mucosa, Submucosa, Muscularis Propria and Serosa, see also lymph nodes and neighboring organ (Goldinger, 2000).

### 1.1.2. Colorectal Cancer

Colorectal Cancer arises in the epithelial cells outlining the lumen of the Colon and Rectum (a Simple Glandular Columnar Epithelium). The cancer is thus called a Colorectal Adenocarcinoma. There are other forms of Colorectal Cancer like Squamous Cell Carcinoma, Sarcoma, Lymphoma and Carcinoid Tumors but they are very rare and altogether constitute less than 2% of the cases in humans, consequently therefor, virtually, 98% of all cancers in the large intestine are adenocarcinomas. They represent one of the prime challenges to the medical profession because they arise in polyps and produce symptoms relatively early and at a stage generally curable by resection (Cotran *et al.*, 1999).

Several lines of evidence indicate that tumorigenesis in humans is a multistep process and these steps reflect genetic alterations that drive the progressive transformation of normal human cells into highly malignant derivatives (Coleman *et al.*, 1997). Pathological analyses reveal lesions that appear to represent the intermediate steps between pre-malignant stages and highly invasive cancers (Hanahan and Weinberg 2000).

### 1.1.3. Symptoms

Colorectal cancers remain asymptomatic for years; symptoms develop insidiously and frequently would have been present for months, sometimes years, before diagnosis. Cecal and right colonic cancers are often called to clinical attention by the appearance of fatigue, weakness, and iron deficiency anemia. The bulky lesions bleed readily and may be discovered at an early stage. Left sided lesions come to attention by producing occult bleeding, changes in the bowel habits, or crampy left-lower-quadrant discomfort. In theory, the chance for early discovery and successful removal should be greater with lesions on the left side because these

patients usually have prominent disturbances in bowel function, such as melena, diarrhea, and constipation (Fong *et al.*, 1995). Cancers of the rectum and sigmoid, however, tend to be more infiltrative at the time of diagnosis than proximal lesion and therefore have a somewhat poorer prognosis. All colorectal tumors spread by direct extension into adjacent structures and by metastasis through the lymphatic and blood vessels. In order of preference, the favored sites of metastatic spread are the regional lymph nodes, liver, lungs, and bones, followed by other sites, including the serosal membrane of peritoneal cavity and brain (Hoebler, 1997).

#### **1.1.4. Diagnosis**

Abdominal Examination, a Digital Rectal Exam and a Rigid Sigmoidoscopy. Physicians usually order examinations like Blood Samples, FOBT (Fecal Occult Blood Test), Colonoscopy, and Barium Enema. Colonoscopy is a very effective way to visualize the entire Colon and Rectum. During Colonoscopy, the bowel can be examined, polyps can be removed, tumors that require surgery can be found and biopsies can be obtained for further pathological examinations. (Cohen *et al.*, 1993)

If Colorectal Cancer is confirmed a Biopsy is examined to reveal the histology, blood tests and Chest X-ray are ordered. An Ultrasound of the liver may also be done. If the cancer is large, especially if it's a rectal cancer, Magnetic Resonance Imaging, Computer Tomography and or Transrectal Ultrasound may be required in order to see if the tumor invades adjacent structures (Kemeny *et al.*, 1993; Parker *et al.*, 1996).

#### **1.1.5. Epidemiology**

The Global population is now estimated to reach approximately 6,1 billion people. Every year, 133 million people are born and 52 million people die. The

median Average life expectancy is 65 years. Where 12% of the population (6,3 million) *die from* Cancers every year, which is the 3rd most common cause of death after Infectious & Parasitic diseases from which 33% (17,3 million) die, and Diseases of the Circulatory System from which 29% (15,3 million) dies every year. There are big differences in what people die from in the Developed and Developing world. Cancers account for 21% of all deaths in the Developed world, and only 9% of all deaths in the under developed world (Goldinger, 2000).

Worldwide about 8 million people *get cancers every year*. About 876,000 people get Colorectal Cancer every year, which makes it the 3rd most common type of cancer to strike people worldwide every year after (1) Lung and (2) Stomach Cancers. Worldwide about 6.3 million people die from cancer every year. Of which 525,000 people die from Colorectal Cancer yearly, which makes it the 3rd common cause of cancer death worldwide after Lung and Stomach Cancers (Ilyas *et al.*, 1996).

Concerning the incidence rate approximately 15 people out of every 100,000 people come down with Colorectal Cancer every year, that differs considerably between countries. It is highest in the Industrialized Countries where it reaches about 50 and lowest in Asia and Africa with Incidence Rates down to 1 (Cohen & Winawer, 1995; Landis *et al.*, 1998). The Incidence Rate for Colorectal Cancer is extremely low in childhood but increases with age (Wingo *et al.*, 1995).

### **1.1.6. Colorectal Polyps**

Polyps of the colorectal mucosa are extraordinarily common in older adult population. Several concepts pertaining to terminology must be emphasized:

- A polyp is a tumorous mass that protrudes into the lumen of the gut.